Trocar Pharma's hypothesis is that a novel clinically validated therapeutic agent that disrupts the infective machinery of SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus 2), on cells in the lung, gastrointestinal (GI) tract and heart, would have a major impact on the devastating COVID-19 pandemic.

​

Our hypothesis is based on observations that the angiotensin converting enzyme 2 (ACE2) is the binding site for SARS-CoV-2, the virus implicated in the current COVID-19 pandemic. This receptor is the same site of entry for the current SARS-CoV-2 virus and the renin angiotensin system (RAS) is highly activated during SARS-CoV-2 infection. More details are available upon request.

​

Trocar Pharma’s COVID-19 therapeutic mitigates the harmful effects of COVID-19 by mediating the host’s response and restoring the cell’s natural homeostasis. Trocar Pharma’s COVID-19 therapeutic will be the first agent to restore the cell’s response to COVID-19 infection, resulting in improved survival and reduced toxicity.